Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ThisCART 19 A

Next Previous
Drug Profile

ThisCART 19 A

Alternative Names: Allogeneic anti-CD19 CAR-T cell injection; ThisCART-19; ThisCART-19-A

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Fundamenta Therapeutics
  • Developer Anhui Provincial Hospital; Suzhou Fundamenta Therapeutics; Zhejiang University
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune haemolytic anaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported B-cell lymphoma; Chronic lymphocytic leukaemia; Lymphoid leukaemia

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in Lymphoid-leukaemia(Recurrent, Second-line therapy or greater) in China (Parenteral, Infusion)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In the elderly, Second-line therapy or greater, In adults) in China (Parenteral, Infusion)
  • 20 Jul 2024 Efficacy, adverse events and pharmacokinetics data from the phase I trial in B-cell lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024) .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top